New individualized risk-assessment technique predicts specific lung cancer survival-rate along with the end results of the treatment, when the condition diagnosed at its early stage.
the novel personalized tools assesses the risk of early stage lung cancer, which uses a set of 29 ECM i.e. extracellular matrix genes has been just devised by the researchers from the National University of Singapore. The examination findings of the study have been revealed in the Nature Communications journal.
According to the author of the study, Prof Lim Chwee Teck from the Department of Biomedical Engineering at the National University of Singapore, the rising number of researchers used to attempt thorough study on the variability or heterogeneity of tumors, will ultimately extend the rates of the development of advanced personalized medicines being the reality.
In a statement, Prof Lim Chwee Teck said that, “When precision medicine meets Big Data, its potential is even greater. With the increase of global joint efforts in sharing large-scale data, we were able to explore the genomic data across multiple cancer types through various databases.”
During the research, the new technology did also determine the panel of 29 particular extracellular matrix (ECM) genes serving as the biomarkers for prognosis and diagnosis, obtaining the abnormal dynamics of cancer growth.
Teck continued saying that, “Our study demonstrates how we can harness and transform unprecedented amount of genomic data into a useful decision-making tool that can be implemented in routine clinical practice. We are excited about the potential of applying our novel bioinformatics approach into the emerging area of liquid biopsy, which serves as an alternative to invasive and painful tissue biopsy.”